Asian Oncology Summit 2015
Shanghai International Convention Center

Shanghai, China
Asian Oncology Summit 2015 
Elsevier Ltd
Shanghai International Convention Center

Schedule of Presentations:

Friday, April 10, 2015
04:15:00 Immune signatures and clinical outcome in breast cancer
12:00:00 Hepatitis C: the next 25 years Homie Razavi
12:50:00 Welcome Address
13:00:00 Progress and challenges in colorectal cancer treatment: towards personalised treatment Eric Van Cutsem
13:30:00 Genomic drivers of hepatocellular carcinoma Jessica Zucman-Rossi
14:30:00 Q&A
15:00:00 Tea, coffee, exhibition and networking
15:30:00 Emend Update - Sponsored Symposium by Merck Sharp and Dohme
16:15:00 Genomics of lung adenocarcinoma Ramaswamy Govindan
16:15:00 How to discover and develop hepatitis drugs – the role of academia for drug discovery R. Bartenschlager
16:40:00 Novel prognostic and predictive markers in breast cancer Soonmyung "Soon" Paik
16:40:00 Current status of malignant mesothelioma in Asia
16:40:00 Novel oral HCV therapies - The era of direct acting antiviral agents Michael P. Manns
17:05:00 The clinical importance of sub-classification in triple-negative breast cancer Binghe Xu
17:05:00 Treatment of patients with non-small-cell lung cancer and brain metastases
17:30:00 Q&A
17:45:00 Drinks reception and poster walk
Saturday, April 11, 2015
03:55:00 Changes in angiogenesis and immune cells in neoadjuvant endocrine therapy and chemotherapy Hironobu Sasano
08:15:00 Curing HCV decreases morbidity and liver as well as non-liver related mortality Harry Janssen
08:15:00 The availability and use of pharmaceutical opioids in the Asia-Pacific region David Currow
08:15:00 Improving the efficiency of cancer drug development: the importance of mechanistic translational studies in early clinical trials Ian Tannock
08:40:00 Clinical studies with a translational component Cornelius J.H. van de Velde
08:40:00 Community-based models of delivering palliative and end-of-life care in India
09:15:00 Q&A
09:30:00 Imaging of the mandible and neck, and routes of tumour entry
09:30:00 An update from the Global Taskforce on Radiotherapy for Cancer Control Mary Gospodarowicz
09:30:00 Discovery of the HBV receptor: impact for prophylaxis and therapy Wenhui Li
09:30:00 Charateristics of Asian patients with renal cell carcinoma: data from the Asian RCC Consortium
09:30:00 Strategic thinking in colorectal cancer: the continuum of care concept Eric van Cutsem
09:30:00 Gene signatures in breast cancer Li Fu
09:55:00 The cancer treatment paradigm in China Yi-Long Wu
09:55:00 The role of innate immunity in hepatitis B Stephen Locarnini
09:55:00 Management of non-clear-cell renal cell carcinoma: What's new? Ravindran Kanesvaran
09:55:00 Medical management of metastatic SCCHN Sai-Hong Ignatius Ou
09:55:00 Clinical application of gene signatures in breast cancer
09:55:00 Prevention of recurrence for early stage HCC: an antiviral or anti-angiogenic strategy? Yi-Hsiang Huang
10:20:00 Gene signatures in colorectal cancer Cornelius J.H. van de Velde
10:20:00 Speaker invited
10:20:00 Carbon ion radiotherapy for head and neck cancers
10:20:00 Long-term effect of NUCs on fibrosis, HCC and cccDNA
10:20:00 Prognostic and predictive markers in renal cell carcinoma: going beyond the clinical factors
10:20:00 Systemic therapy for cholangiocarcinoma: novel targets Andrew Zhu
10:45:00 Q&A
10:45:00 Q&A
11:00:00 Tea, coffee, exhibition and networking
12:15:00 Translational research in the field of clinical oncology in recent years in China
12:45:00 Liver cancer screening in high-risk populations Morris Sherman
13:15:00 Occult HBV Man-Fung Yuen
13:45:00 Q&A
14:00:00 Tea, coffee, exhibition and networking
15:05:00 Surgical challenges in Asian women with breast cancer Won-Shik Han
15:05:00 DLBCL: How do we improve results? Bertrand Coiffier
15:05:00 Next generation of targeted therapy for NSCLC Pasi A Janne
15:05:00 Drug resistance and the tumour microenvironment: inhibition of autophagy as a strategy to improve clinical benefit Ian Tannock
15:05:00 HBsAg levels in the natural history and during antiviral therapy of hepatitis B Markus Cornberg
15:05:00 Optimal management of metastatic hepatocellular carcinoma Andrew Zhu
15:30:00 Surgical management of gastric cancer in Asia
15:30:00 Determining factors for neoadjuvant therapy in Chinese patients Zhimin Shao
15:30:00 Speaker invited
15:30:00 Management of patients with SCLC in Asia
15:30:00 Molecular characterisation of the tumour microenvironment Xin-yuan Guan
15:30:00 Hepatitis B cure: the new challenge in hepatitis B therapy Fabien Zoulim
15:55:00 Tumour and stroma interactions Xiu-wu Bian
15:55:00 Improving the clinical outcome of unmanipulated haploidentical transplantation
15:55:00 cMET as a target for treatment of NSCLC Yi-Long Wu
15:55:00 Anti-EGFR treatment in metastatic colorectal cancer: which patient, and how, in 2016 Ka-On Lam
15:55:00 Towards global eradication of HBV: lessons learned from succesful national programmes Ding-Shinn Chen
16:30:00 Tea, coffee, exhibition and networking
Sunday, April 12, 2015
06:00:00 New Presentation
06:00:00 New Presentation
08:30:00 Risk score for HCC development in HBV Grace Wong
08:30:00 Translational research on biomarkers for early diagnosis of prostate cancer Yinghao Sun
08:30:00 Translational research on biomarkers for early diagnosis of prostate cancer Yinghao Sun
08:30:00 Tyrosine kinase inhibitor resistance in GIST: mechanisms and management Yoon-Koo Kang
08:55:00 Gastric cancer prevention by eradication of Helicobacter pylori in China Wei-cheng You
08:55:00 Impact of antiviral therapies on liver cancer development Massimo Colombo
08:55:00 Is active surveillance a feasible option for low-risk prostate cancer in an Asian population?
09:20:00 Q&A
09:30:00 HEV in the East - endemic or pandemic Mohammad Khuroo
09:30:00 Regenerative medicine for oesophageal reconstruction after cancer treatment Koji Kono
09:30:00 Which patients with advanced ovarian cancer should be selected for primary debulking or neoadjuvant chemotherapy Ignace Vergote
09:30:00 Natural products in cancer immunology
09:30:00 Screening for and managing adverse endocrine outcomes in long-term survivors of childhood and adolescent cancer
09:55:00 The role of the microbiome in colorectal cancer
09:55:00 The importance of stem cells in breast cancer: why should you already be thinking about stem cells when treating your patients
09:55:00 Advances in targeted therapy for ovarian cancer
09:55:00 HEV in the West – a zoonotic disease Nassim Kamar
09:55:00 Cancer treatment and fertility: patient selection and strategies for fertility preservation in children and young adults Rod Mitchell
10:20:00 Recent advances in molecularly targeted agents and immunotherapy for gastric cancer
10:20:00 Implementation of HPV DNA testing in the Asia-Pacific region Y.- L. Qiao
10:20:00 Combinations or stand alone? How to best utilise immunotherapies
10:20:00 HEV vaccines – efficacy and indications – the Chinese experience Jun Zhang
10:20:00 HPS axis effects Andrew Toogood
10:45:00 Q&A
11:00:00 Tea, coffee, exhibition and networking
12:00:00 Viral hepatitis and liver transplantation
12:10:00 How to write the perfect paper
12:20:00 Global strategies to combat HAV Daniel Shouval
12:40:00 HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12
13:00:00 Q&A
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.